BAZ1B

Across TCGA pan-cancer cohorts, BAZ1B mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of BAZ1B’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where BAZ1B mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types BAZ1B is over-expressed in tumor.

HNSC, COAD, and CCRCC are the cancer types where BAZ1B tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in BAZ1B mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	IV	+0.611	<.001	11	view →
COAD	Male	All	+0.496	<.001	11	view →
CCRCC	Male	All	+0.299	<.001	11	view →
LSCC	Male	II,III,IV	+0.570	<.001	8	view →
LUAD	Male	II,III,IV	+0.281	<.001	8	view →
OV	All	All	+0.274	.025	2	view →
PDAC	Female	All	+0.103	.031	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

BAZ1B–HNSC

Open the HNSC breakdown →